Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
Related Posts
Country Managers Meeting in Lebanon on early September
News / September 30, 2014
Job opportunities: Experienced CRAs in Jordan, Egypt and Tunisia
News / October 9, 2013